Two Sigma Investments
AXSM icon

Two Sigma Investments’s Axsome Therapeutics AXSM Stock Holding History

Two Sigma Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+4,400
New +$954K ﹤0.01% 3565

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Two Sigma Investments's AXSM Position: Q2 2026 in Review

Two Sigma Investments increased its Axsome Therapeutics (AXSM) stake by 107% in Q2 2026, buying an estimated $75.2M and bringing the position to 669,478 shares worth $164M. The position accounts for 0.12% of the portfolio, ranked #187.

Two Sigma Investments first reported a position in AXSM in Q4 2020 and has held it in 11 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Two Sigma Investments held 669,478 shares of Axsome Therapeutics worth $164M as of Q2 2026.
  • Two Sigma Investments bought 346,700 Axsome Therapeutics shares in Q2 2026, an estimated $75.2M.
  • Axsome Therapeutics made up 0.12% of Two Sigma Investments's portfolio in Q2 2026, its #187 holding.
  • Two Sigma Investments first reported a position in Axsome Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.